InMed appoints Neil Klompas to board, effective October 9, 2025

InMed Pharmaceuticals Inc.

Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.
Klompas brings 30+ years experience; was President/COO and CFO at Zymeworks (NASDAQ: ZYME), led 2017 IPO.
Currently CEO of Augerex Life Science Corp, serves on boards of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences.
He will receive standard non-employee director compensation: US$50k annual retainer plus potential committee fees.
No related party transactions or family relationships with any director or officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.